24 Mar
  • By Brandon
  • Cause in

CureDuchenne Continues Focus as Champions for the Duchenne Community with Launch of Innovative Suite of Online Resources

NEWPORT BEACH, Calif., (March 24, 2020) – CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, is rolling out a comprehensive suite of online resources for the Duchenne community. This suite of resources is aimed at engaging the community to maintain continuity of care and community building in the current times […]

READ MORE
12 Mar
  • By Brandon
  • Cause in

Global research nonprofit CureDuchenne joins Pfizer to Host Free Webinar on Pfizer’s Advancement to Phase III Gene Therapy Clinical Trial

NEWPORT BEACH, Calif., (March 10, 2020) – CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their advancement to Phase III Clinical Trial for PF-06939926. The webinar will take place on Wednesday, March 11:00am PT/2:00pm ET and features Dr. Beth Belluscio, Pfizer Global Clinical […]

READ MORE
04 Mar
  • By Brandon
  • Cause in

Napa In Newport Helps Raise over $1 million To Help Find a Cure for Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif., (March 4, 2020) – Hundreds gathered at the Monarch Beach Resort on Saturday, February 29 to enjoy the best of Napa Valley wineries and help find a cure for Duchenne muscular dystrophy. The sixth annual Napa in Newport wine auction, sponsored by Porsche, raised more than $1 million dollars to support CureDuchenne’s mission to extend and […]

READ MORE
Cook Family Photo
10 Feb
  • By Greg Freeman
  • Cause in

Scientific Peer Review of Congressionally Directed Medical Research Programs’ Duchenne Muscular Dystrophy Research Program for the Department of Defense

The Congressionally Directed Medical Research Programs’ (CDMRP), Duchenne Muscular Dystrophy Research Program (DMDRP) consumer advocates Tiffany Cook and Clint M. Porter recently participated in the evaluation of research applications submitted to the DMDRP.  Tiffany Cook and Clint M. Porter were nominated for participation in the program by CureDuchenne, Newport Beach, CA.  As consumer reviewers, they […]

READ MORE
Vivli Logo
21 Jan
  • By Greg Freeman
  • Cause in

Global research nonprofit CureDuchenne joins Vivli to share clinical trial data for treating muscular dystrophy

CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will contribute patient-level clinical data to the Vivli platform, making it available to other researchers around the world. The data will augment existing studies that are available to request on the Vivli platform, which currently hosts data from over 4,700 trials. […]

READ MORE
Shape Therapeutics Logo
05 Nov
  • By Greg Freeman
  • Cause in

Shape Therapeutics, Inc. raises $35.5M Series A financing, led by NEA and announces the formation of a world-class Scientific Advisory Board, to advance a first-in-class RNA editing gene therapy platform focused on curing genetic diseases.

  The Shape Therapeutics RNAfixTM editing platform uses fully human components and avoids risks associated with in vivo CRISPR-based technologies. The SAB, comprised of industry pioneers in the field of genetics and synthetic biology, includes George Church Ph.D. (Harvard-MIT Health Sciences & Technology), James Collins Ph.D. (Harvard-MIT Health Sciences & Technology), and Don Cleveland Ph.D. […]

READ MORE
12 Oct
  • By Greg Freeman
  • Cause in

Nonprofit CureDuchenne Launches Biobank to Fuel Research for Duchenne Muscular Dystrophy

NEWPORT BEACH, CALIF. – (October 12, 2019) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (Duchenne), announced today it has initiated the development of a biobank for Duchenne.   The CureDuchenne Biobank is dedicated to empowering Duchenne research and the […]

READ MORE
27 Sep
  • By Greg Freeman
  • Cause in

CureDuchenne Invests in Chameleon Biosciences to Support EVADERTM, a Next Generation Adeno Associated Virus Based Gene Therapy Platform Technology

Investment will help advance development of gene therapy technology offering resistance to pre-existing antibodies, enhanced gene delivery and the potential for repeat dosing. NEWPORT BEACH, CALIF. — (September 27, 2019) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), […]

READ MORE
19 Sep
  • By Greg Freeman
  • Cause in

CureDuchenne Appoints Lianna Orlando, PhD, to the Position of Senior Director of Research

Newport Beach, CA – (September 19, 2019) – CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Lianna Orlando, PhD has joined the team as Senior Director of Research.  In this role, Orlando will help identify and evaluate strategic investments aimed at developing treatments for […]

READ MORE